[go: up one dir, main page]

WO2016018178A4 - Complex anti-nicotine agent - Google Patents

Complex anti-nicotine agent Download PDF

Info

Publication number
WO2016018178A4
WO2016018178A4 PCT/RU2015/000438 RU2015000438W WO2016018178A4 WO 2016018178 A4 WO2016018178 A4 WO 2016018178A4 RU 2015000438 W RU2015000438 W RU 2015000438W WO 2016018178 A4 WO2016018178 A4 WO 2016018178A4
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
agent
paragraph
complex anti
pharmaceutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2015/000438
Other languages
French (fr)
Russian (ru)
Other versions
WO2016018178A1 (en
Inventor
Дмитрий Евгеньевич ДЕНИСОВ
Людмила Борисовна ТИМИРОВА
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016018178A1 publication Critical patent/WO2016018178A1/en
Publication of WO2016018178A4 publication Critical patent/WO2016018178A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to pharmaceutics and para-pharmaceutics, and more particularly to agents for the cessation of smoking. Proposed is a complex anti-nicotine agent, containing nicotine or a nicotine-like alkaloid and the amino acids theanine 50-200 mg and tryptophan 8-50 mg in 1 dose. The agent can be made available in the form of sweets, chewing gum, tablets, drops, syrups and transdermal systems.

Claims

ИЗМЕНЁННАЯ ФОРМУЛА ИЗОБРЕТЕНИЯ получена Международным бюро 16 февраля 2016 (16.02.2016) MODIFIED INVENTION FORMULA Received by the International Bureau on February 16, 2016 (February 16, 2016) [Пункт 1] 1. Антиникотиновое средство, содержащее в 1 дозе теанин 50-200 мг и триптофан 8-50 мг. [Paragraph 1] 1. Antinicotinic agent containing in one dose of theanine 50–200 mg and tryptophan 8–50 mg. [Пункт 2] 2. Антиникотиновое средство по п. 1, отличающееся тем, что может дополнительно содержать никотин в количестве 1-1,5 мг.  [Paragraph 2] 2. The anti-nicotine agent according to claim 1, characterized in that it may additionally contain nicotine in an amount of 1-1.5 mg. [Пункт 3] 3. Антиникотиновое средство по п. 1, отличающееся тем, что может дополнительно содержать алкалоид с никотиноподобным действием, выбранный из группы: лобелии гидрохлорид 1-1,5 мг, анабазин гид- рохлорид 1-2 мг, цитизин 0,5-1 мг.  [Paragraph 3] 3. The anti-nicotine agent according to claim 1, characterized in that it may additionally contain an alkaloid with nicotine-like action, selected from the group: lobelia hydrochloride 1-1.5 mg, anabasin hydrochloride 1-2 mg, cytisine 0 5-1 mg. ИЗМЕНЁННЫЙ ЛИСТ (СТАТЬЯ 19) CHANGED SHEET (ARTICLE 19)
PCT/RU2015/000438 2014-07-29 2015-07-10 Complex anti-nicotine agent Ceased WO2016018178A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014131493/15A RU2572720C1 (en) 2014-07-29 2014-07-29 Combined antinicotinic agent
RU2014131493 2014-07-29

Publications (2)

Publication Number Publication Date
WO2016018178A1 WO2016018178A1 (en) 2016-02-04
WO2016018178A4 true WO2016018178A4 (en) 2016-03-24

Family

ID=55087022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2015/000438 Ceased WO2016018178A1 (en) 2014-07-29 2015-07-10 Complex anti-nicotine agent

Country Status (2)

Country Link
RU (1) RU2572720C1 (en)
WO (1) WO2016018178A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG67408B1 (en) 2019-04-12 2022-01-17 Софарма Ад Oral drug composition with plant alkaloid for treatment of addictions
CN115813011A (en) * 2022-12-30 2023-03-21 东莞市吉纯生物技术有限公司 Preparation method and application of atomized liquid containing theanine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
JP3730522B2 (en) * 2000-07-21 2006-01-05 太陽化学株式会社 Smoking craving suppression composition
ES2499067T3 (en) * 2005-10-13 2014-09-26 Nitto Denko Corporation Transdermal preparation of nicotine and its production method
KR20110063545A (en) * 2008-09-17 2011-06-10 용린 리앙 Independence, tobacco addiction-treatment and detox filter bars and tobacco pipes, and methods of making the same

Also Published As

Publication number Publication date
RU2572720C1 (en) 2016-01-20
WO2016018178A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
MY191297A (en) Oral solid formulation containing irinotecan and method of preparing the same
WO2013109388A3 (en) 1,5-naphthyridine derivatives and melk inhibitors containing the same
MX2019012454A (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride.
MX385518B (en) FORMULATION HAVING ENHANCED pH-DEPENDENT DRUG RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
WO2013169746A3 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
WO2016018178A4 (en) Complex anti-nicotine agent
MX2015014958A (en) Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same.
WO2014049585A3 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
WO2014167577A3 (en) "synthesis of dabigatran"
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
HK1243704A1 (en) Novel regimens of tafenoquine for prevention of malaria in malaria-naïve subjects
EA202090913A1 (en) COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON
HK1245095A1 (en) Pharmaceutical combination of everolimus with dactolisib
HK1249408A1 (en) Mdm2 inhibitors for treating uveal melanoma
WO2016091805A3 (en) Naloxone monopreparation and multi-layer tablet
EA201892842A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID
MX394413B (en) Pharmaceutical composition containing clomipramine and preparation method therefor
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15828306

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15828306

Country of ref document: EP

Kind code of ref document: A1